NeuroTheryX Canada Ltd.

What NeuroTheryX Canada Ltd. does

NeuroTheryX Canada Ltd. is a privately held biotechnology company founded in 2017 and headquartered at JLABs Toronto in Toronto, Ontario, Canada. The company is organized around a proprietary technology platform that combines genetic target identification, phenotype-based biological models, and a focused chemistry approach to identify and evaluate candidate pharmaceutical and nutraceutical products. Its stated emphasis is on speed, fidelity, and predictability in establishing a diversified development pipeline.

The company operates three product lines: pharmaceutical projects (small molecule oral formulation drugs for Primary Progressive Multiple Sclerosis, AI and phenotype-based design of synthetic new chemical entity cannabinoids for pain management, and small molecule drugs for fat thermogenesis); nutraceutical projects (synergistic natural extract combinations engineered to pharmaceutical standards across six wellness targets including focus, pain, fat thermogenesis, innate immunity, cognitive health, and sleep); and functional foods (unique extract combinations tested for bioactivity and licensed for use in consumer packaged goods).

NeuroTheryX's business model is B2B licensing, developing pipeline assets for out-licensing to pharmaceutical, nutraceutical, and CPG companies rather than selling directly to end consumers. The company is described as targeting a horizontal customer base spanning healthcare, wellness, and consumer goods. As of the available data, NeuroTheryX has six employees, no disclosed revenue, and no recorded funding rounds, indicating an early-stage, pre-commercial operating profile.

Name

NeuroTheryX Canada Ltd.

Legal name

NeuroTheryX Canada Ltd.

Website

https://neurotheryx.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroTheryX Canada Ltd. is a Toronto-based privately held biotechnology company that uses a proprietary platform combining genetic targets, phenotype-based models, and AI to develop pharmaceutical, nutraceutical, and functional food pipeline assets for B2B licensing to pharma and CPG companies.

Ownership category

akta.pro rank

Product category

Biotechnology / Pharmaceutical R&D

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Drug discovery platform
• Pharmaceutical development
• Nutraceutical formulations
• Functional food ingredients
• Synthetic cannabinoid therapeutics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development: Development of small molecule therapeutics for clinical development including treatments for Primary Progressive Multiple Sclerosis, synthetic cannabinoids for pain management, and fat thermogenesis drugs
2. Nutraceutical Products: Development and licensing of synergistic natural extract combinations engineered using pharmaceutical standards for wellness targets including focus, pain management, fat thermogenesis, innate immunity, cognitive health, and sleep wellness
3. Functional Foods: Unique functional extract combinations tested for bioactivity and licensed for use in Consumer packaged goods (CPGs)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

NeuroTheryX is a biotechnology company that discovers and develops a pipeline of pharmaceutical small molecule therapeutics (including treatments for Primary Progressive Multiple Sclerosis, AI-designed synthetic cannabinoids for pain management, and fat thermogenesis drugs), nutraceutical formulations (synergistic natural extract combinations for focus, pain, immunity, cognition, and sleep), and functional food extract combinations for consumer packaged goods. Pipeline assets are developed for licensing or partnership with pharmaceutical, nutraceutical, and CPG companies. The NeuroTheryX Technology Platform (genetic targets combined with phenotype-based models and focused chemistry) underpins all discovery and development activities.

Product overview

NeuroTheryX is a biotechnology company developing a diverse pipeline of products across three main categories: Pharmaceutical Projects (small molecule therapeutics for Multiple Sclerosis, pain management, and fat thermogenesis), Nutraceutical Projects (natural extract combinations for focus, pain, immunity, cognition, and sleep), and Functional Foods (bioactive extract combinations licensed for consumer packaged goods). The NeuroTheryX Technology Platform underpins all projects, combining predictive biology-driven models with targeted chemistry for drug and nutraceutical discovery and development.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Projects Development of small molecule oral formulation therapeutics for clinical development, including treatments for Primary Progressive Multiple Sclerosis, AI and phenotype-based design of synthetic new chemical entity cannabinoids for pain management, and small molecule drugs for fat thermogenesis. For licensing to pharmaceutical companies.
• Nutraceutical Projects Synergistic natural extract combinations engineered using pharmaceutical standards to address wellness targets including focus and functionality, pain management, fat thermogenesis, innate immunity, cognitive health and vitality, and sleep wellness. Developed for licensing to nutraceutical and wellness companies.
• Functional Foods Unique functional extract combinations tested for bioactivity and licensed for use in Consumer Packaged Goods (CPG). Targeted at food and beverage companies seeking functional ingredients.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• JLABs TorontocoreStrategic or Co-development PartnerNeuroTheryX is a resident company of JLABs Toronto, which provides access to lab space, mentorship, investor networks, and the broader biotech innovation ecosystem. JLABs is Johnson & Johnson's life science incubator program, offering startups infrastructure and resources for development.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Nuritas: AI-driven peptide discovery company developing bioactive ingredients for functional food, nutraceutical, and pharmaceutical applications. Closely comparable business model, using AI and biology-driven discovery to produce ingredients for CPG and pharma licensing.
• Atomwise: AI-driven small molecule drug discovery company using structure-based design and virtual screening. Comparable as a platform biotech applying AI and computational chemistry to identify novel small molecule candidates across multiple therapeutic areas, similar to NeuroTheryX's AI-designed cannabinoid and PPMS programs.

Emerging players

• Brightseed: AI-driven bioactive discovery company focused on identifying plant-based compounds for health and nutrition applications. Comparable as a science-driven discovery platform bridging functional ingredients and CPG/health applications, similar to NeuroTheryX's nutraceutical and functional food tracks.
• InVivo AI: Montreal-based AI drug discovery company focused on CNS and rare neurological diseases. Comparable as a fellow Canadian early-stage biotech applying AI to small molecule discovery in CNS/neurology indications that overlap with NeuroTheryX's PPMS and pain programs.
• BenchSci: Toronto-based AI-powered biomedical research platform that helps scientists select reagents and accelerate preclinical research. Comparable to NeuroTheryX as a fellow Toronto-based, JLABs-affiliated biotech using AI and biology-driven approaches to accelerate early-stage discovery.
• Cyclica: Toronto-based AI-driven polypharmacology platform for drug discovery. Directly comparable as another Toronto biotech using AI-augmented computational biology for early-stage small molecule discovery across multiple therapeutic targets.

Broad incumbents

• GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer in cannabinoid-based pharmaceuticals, now part of Jazz Pharmaceuticals, with FDA-approved cannabinoid therapies. Comparable as the established incumbent in the synthetic cannabinoid therapeutic space that NeuroTheryX's pain program would target.
• Roche: Large pharmaceutical company with Ocrevus, the leading approved therapy for Primary Progressive Multiple Sclerosis. Comparable as the dominant incumbent in NeuroTheryX's lead PPMS indication and a likely potential licensing counterparty.
• Recursion Pharmaceuticals: Publicly-traded AI-enabled drug discovery company combining high-throughput biology with machine learning to build a broad pipeline. Comparable as a more advanced, scaled version of the same 'biology-driven models plus AI/chemistry' platform thesis that NeuroTheryX is pursuing.

Regional players

• AbCellera: Vancouver-based antibody discovery platform that built its business on technology-platform licensing to pharma. Comparable as a Canadian biotech that successfully commercialized an early-stage discovery platform through major pharma partnerships.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/neurotheryx

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroTheryX Canada Ltd.